Cytotoxic drugs are capable of interacting directly with DNA and
such drugs can interact with the biosynthesis of proteins, and
hence, are used as chemotherapeutic agents. Dactinomycin,
Epirubicin, Bleomycin, Idarubicin, and Daunorubicin are some key
examples of cytotoxic drugs.
WILMINGTON, Del., July 11,
2024 /PRNewswire/ -- Owing to various key industry
forces, the global injectable cytotoxic drug market is
advance at a moderate CAGR of 6.8% through the forecast era.
This development is projected to help the competitive space
reach USD 38.2 billion by
2034. The last measured size of the ecosystem was
USD 18.6 billion in 2023.
The prevalence of cancer has been a key factor that drives the
demand for many sectors. Various therapeutics and treatments are
required to be given to cancer patients, which drives the demand
for such therapies and treatments.
The upsurge in rheumatoid arthritis and multiple sclerosis is
driving the need for advanced therapeutics. To cater to the growing
demand, medical professionals have been investing more in the
development of new drugs that can reduce the reaction of the human
body, elevating the success rate of the treatment.
Clinical testing and development of injectable drugs are gaining
momentum. As a result of such factors, the introduction of such
drugs in the market is gaining traction. Owing to the rising demand
across the world, this factor proves to be a boon for the
healthcare sector.
Download Sample PDF
Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83576
Injectable Cytotoxic Drug Market Report Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020–2022
|
Size in 2023
|
US$ 18.6 Bn
|
Forecast (Value) in
2034
|
US$ 38.2 Bn
|
Growth Rate
(CAGR)
|
6.8 %
|
No. of
Pages
|
145
Pages
|
Segments
covered
|
Drug Class,
Application, Sales Channel
|
The rising investments in research and development are likely to
spur prospects for key players in the ecosystem. Innovations in
drug formulation and delivery of such drugs become feasible, which
helps the ecosystem grow.
The growing demand for non-invasive treatments is driving the
requirement for injectable drugs. The delivery of such medicines
can turn out to be more efficient as intravenous drug applications
can accelerate treatment action speed.
The awareness of injectable cytotoxic drugs is spurring.
Healthcare experts have streamlined the use of such drugs in the
initial treatments of cancer. Owing to the standardization of
treatments to cater to the heterogeneity of cancer cases, such
drugs can play a pivotal role in shaping the competitive space.
Pertaining to narrowing down the scope of cancer treatment,
immunotherapy, and other treatments are gaining momentum.
Injectable cytotoxic drugs play a crucial role in terms of
increasing the efficiency of such treatments. This acts as a key
growth driver for the progress of the ecosystem. The rising
investments in the healthcare infrastructure in various countries
are expected to push the growth of the injectable cytotoxic drug
market further.
Key Findings from the Market Report
- The injectable cytotoxic drug market is segmented based on
different key parameters. Based on the drug class, alkylating drugs
are likely to govern the ecosystem. Due to the growing prevalence
of mast cell tumors, the demand for such drugs is likely to
proliferate.
- Antimetabolites form another contributor to the said segment.
Due to the growing emphasis on the prevention of cancer mutation,
such drugs are used.
- Owing to the growing prevalence of rheumatoid arthritis, the
demand for injectable drugs in the sector is likely to increase.
This helps the category contribute the highest to the competitive
space.
- Based on sales channels, hospitals are expected to govern the
market due to the growing demand for better medical assistance for
cancer.
Unlock Growth Potential in Your Industry! Download PDF
Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83576
Regional Profile
- Owing to the development of the healthcare infrastructure in
Asia-Pacific, the scope for
the competitive space in the region is likely to increase
drastically.
- European companies are focusing on research and
development, which might introduce new drugs and augment the
injectable cytotoxic drug market in the region.
- Technological advancements in North America are likely to assist the
progress of the industry in the region.
Competitive Landscape
- Johnson & Johnson is a key player in the competitive
landscape and the business offers products for many verticals, like
pulmonary hypertension, cardiovascular diseases, and
neuroscience.
- Sanofi S.A. is another player offering products like
Aldurazyme, Amaryl, and Aubagio.
- Eli Lilly and Company produces products like
Dulaglutide, Insulin Lispro, and Insulin Delivery Medical
Devices.
Key Players
- Johnson & Johnson
- Sanofi S.A.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- Amgen Inc.
Key Developments in the Injectable Cytotoxic
Drug Market
- In May 2024, Sanofi S.A.
acquired Inhibrx Inc. This strategic move has bolstered the
position of the organization in the market.
- In June 2024, Johnson &
Johnson acquired Proteologix Inc. This helped the organization
expand in the competitive space.
Email Directly Here with Detail
Information: sales@transparencymarketresearch.com
Market Segmentation
Drug Class
- Alkylating Drugs
- Cytotoxic Antibodies
- Antimetabolites
- Others (Plant Alkaloids, etc.)
Application
- Oncology
- Rheumatoid Arthritis
- Others (Multiple Sclerosis, etc.)
Sales Channel
- Hospital Pharmacies
- Drug and Retail Stores
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase the Report for Market-Driven Insights:
https://www.transparencymarketresearch.com/checkout.php?rep_id=83576<ype=S
More Trending Reports by Transparency Market Research
–
Pediatric Perfusion Products Market: The global
pediatric perfusion products market is likely to expand at a
CAGR of 7.3% from 2022 to 2031. A congenital heart case is
one where abnormalities are detected in the heart of an infant at
birth. Growth in the prevalence of congenital heart disease is
expected to boost the market size for pediatric perfusion products
during the forecast period.
Teeth Whitening Products Market: The global teeth
whitening products market is projected to flourish at a CAGR of
6.2% from 2022 to 2031. As per the report published by TMR, a
valuation of US$ 10.6 billion is anticipated for
the market in 2031. As of 2023, the demand for is expected to close
at US$ 6.5 billion.
Neurosurgery Market - The global neurosurgery
market is projected to advance at a CAGR of 4.5% from 2024
to 2034
Multiplex PCR Market - The global multiplex
PCR market is projected to expand at a CAGR of 8.2% during
the forecast period from 2024 to 2034
About Transparency Market Research
Transparency Market Research, a global market research
company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter|
Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/injectable-cytotoxic-drug-market-to-progress-at-a-cagr-of-6-8-reaching-usd-38-2-billion-by-2034---report-by-transparency-market-research-inc-302194694.html
SOURCE Transparency Market Research